PubMed:9746003
Annnotations
LitCoin-entities
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| 276 | 21-34 | ChemicalEntity | denotes | carbamazepine | MESH:D002220 |
| 277 | 39-49 | ChemicalEntity | denotes | vigabatrin | MESH:D020888 |
| 278 | 61-77 | DiseaseOrPhenotypicFeature | denotes | absence seizures | MESH:D004832 |
| 279 | 79-92 | ChemicalEntity | denotes | Carbamazepine | MESH:D002220 |
| 280 | 97-107 | ChemicalEntity | denotes | vigabatrin | MESH:D020888 |
| 281 | 139-155 | DiseaseOrPhenotypicFeature | denotes | absence seizures | MESH:D004832 |
| 282 | 271-284 | ChemicalEntity | denotes | carbamazepine | MESH:D002220 |
| 283 | 324-334 | ChemicalEntity | denotes | Vigabatrin | MESH:D020888 |
| 284 | 445-458 | ChemicalEntity | denotes | carbamazepine | MESH:D002220 |
| 285 | 486-501 | DiseaseOrPhenotypicFeature | denotes | myoclonic jerks | MESH:D009207 |
| 286 | 535-548 | ChemicalEntity | denotes | carbamazepine | MESH:D002220 |
| 287 | 595-605 | ChemicalEntity | denotes | vigabatrin | MESH:D020888 |
| 288 | 694-710 | ChemicalEntity | denotes | sodium valproate | MESH:D014635 |
| 289 | 712-723 | ChemicalEntity | denotes | lamotrigine | MESH:D000077213 |
| 290 | 728-740 | ChemicalEntity | denotes | ethosuximide | MESH:D005013 |
LitCoin-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-78 | Sentence | denotes | Inappropriate use of carbamazepine and vigabatrin in typical absence seizures. |
| T2 | 79-156 | Sentence | denotes | Carbamazepine and vigabatrin are contraindicated in typical absence seizures. |
| T3 | 157-323 | Sentence | denotes | Of 18 consecutive referrals of children with resistant typical absences only, eight were erroneously treated with carbamazepine either as monotherapy or as an add-on. |
| T4 | 324-382 | Sentence | denotes | Vigabatrin was also used in the treatment of two children. |
| T5 | 383-549 | Sentence | denotes | Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine. |
| T6 | 550-643 | Sentence | denotes | Absences were aggravated in both cases where vigabatrin was added on to concurrent treatment. |
| T7 | 644-765 | Sentence | denotes | Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination. |
LitCoin-GeneOrGeneProduct-v0
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 69-77 | GeneOrGeneProduct | denotes | seizures |
| T2 | 147-155 | GeneOrGeneProduct | denotes | seizures |
| T3 | 157-162 | GeneOrGeneProduct | denotes | Of 18 |
| T4 | 383-392 | GeneOrGeneProduct | denotes | Frequency |
| T5 | 496-501 | GeneOrGeneProduct | denotes | jerks |
| T6 | 583-588 | GeneOrGeneProduct | denotes | cases |
LitCoin-GeneOrGeneProduct-v2
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 69-77 | GeneOrGeneProduct | denotes | seizures |
| T2 | 147-155 | GeneOrGeneProduct | denotes | seizures |
| T3 | 383-392 | GeneOrGeneProduct | denotes | Frequency |
LitCoin-Disease-MeSH
| Id | Subject | Object | Predicate | Lexical cue | originalLabel |
|---|---|---|---|---|---|
| T1 | 61-77 | DiseaseOrPhenotypicFeature | denotes | absence seizures | D012640 |
| T2 | 139-155 | DiseaseOrPhenotypicFeature | denotes | absence seizures | D012640 |
| T3 | 486-501 | DiseaseOrPhenotypicFeature | denotes | myoclonic jerks | D009207 |
LitCoin_Mondo_095
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 61-77 | DiseaseOrPhenotypicFeature | denotes | absence seizures | 0010826 |
| T2 | 139-155 | DiseaseOrPhenotypicFeature | denotes | absence seizures | 0010826 |
LitCoin-MeSH-Disease-2
| Id | Subject | Object | Predicate | Lexical cue | ID: |
|---|---|---|---|---|---|
| T1 | 61-77 | DiseaseOrPhenotypicFeature | denotes | absence seizures | D012640 |
| T2 | 139-155 | DiseaseOrPhenotypicFeature | denotes | absence seizures | D012640 |
| T3 | 486-501 | DiseaseOrPhenotypicFeature | denotes | myoclonic jerks | D009207 |
LitCoin-MONDO_bioort2019
| Id | Subject | Object | Predicate | Lexical cue | #label |
|---|---|---|---|---|---|
| T1 | 61-77 | DiseaseOrPhenotypicFeature | denotes | absence seizures | D012640 |
| T2 | 139-155 | DiseaseOrPhenotypicFeature | denotes | absence seizures | D012640 |
| T3 | 486-501 | DiseaseOrPhenotypicFeature | denotes | myoclonic jerks | D009207 |
LitCoin-Chemical-MeSH-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | ID: |
|---|---|---|---|---|---|
| T1 | 21-34 | ChemicalEntity | denotes | carbamazepine | D002220|http://purl.obolibrary.org/obo/CHEBI_3387 |
| T3 | 39-49 | ChemicalEntity | denotes | vigabatrin | http://purl.obolibrary.org/obo/CHEBI_63638 |
| T4 | 79-92 | ChemicalEntity | denotes | Carbamazepine | D002220|http://purl.obolibrary.org/obo/CHEBI_3387 |
| T6 | 97-107 | ChemicalEntity | denotes | vigabatrin | http://purl.obolibrary.org/obo/CHEBI_63638 |
| T7 | 271-284 | ChemicalEntity | denotes | carbamazepine | D002220|http://purl.obolibrary.org/obo/CHEBI_3387 |
| T9 | 324-334 | ChemicalEntity | denotes | Vigabatrin | http://purl.obolibrary.org/obo/CHEBI_63638 |
| T10 | 445-458 | ChemicalEntity | denotes | carbamazepine | D002220|http://purl.obolibrary.org/obo/CHEBI_3387 |
| T12 | 535-548 | ChemicalEntity | denotes | carbamazepine | D002220|http://purl.obolibrary.org/obo/CHEBI_3387 |
| T14 | 595-605 | ChemicalEntity | denotes | vigabatrin | http://purl.obolibrary.org/obo/CHEBI_63638 |
| T15 | 694-710 | ChemicalEntity | denotes | sodium valproate | D014635|http://purl.obolibrary.org/obo/CHEBI_9925 |
| T17 | 712-723 | ChemicalEntity | denotes | lamotrigine | D000077213|http://purl.obolibrary.org/obo/CHEBI_6367 |
| T19 | 728-740 | ChemicalEntity | denotes | ethosuximide | D005013|http://purl.obolibrary.org/obo/CHEBI_4887 |
LitCoin-training-merged
| Id | Subject | Object | Predicate | Lexical cue | #label | ID: |
|---|---|---|---|---|---|---|
| T19 | 728-740 | ChemicalEntity | denotes | ethosuximide | http://purl.obolibrary.org/obo/CHEBI_4887|D005013 | |
| T17 | 712-723 | ChemicalEntity | denotes | lamotrigine | http://purl.obolibrary.org/obo/CHEBI_6367|D000077213 | |
| T15 | 694-710 | ChemicalEntity | denotes | sodium valproate | http://purl.obolibrary.org/obo/CHEBI_9925|D014635 | |
| T14 | 595-605 | ChemicalEntity | denotes | vigabatrin | http://purl.obolibrary.org/obo/CHEBI_63638 | |
| T12 | 535-548 | ChemicalEntity | denotes | carbamazepine | http://purl.obolibrary.org/obo/CHEBI_3387|D002220 | |
| T10 | 445-458 | ChemicalEntity | denotes | carbamazepine | http://purl.obolibrary.org/obo/CHEBI_3387|D002220 | |
| T9 | 324-334 | ChemicalEntity | denotes | Vigabatrin | http://purl.obolibrary.org/obo/CHEBI_63638 | |
| T7 | 271-284 | ChemicalEntity | denotes | carbamazepine | http://purl.obolibrary.org/obo/CHEBI_3387|D002220 | |
| T6 | 97-107 | ChemicalEntity | denotes | vigabatrin | http://purl.obolibrary.org/obo/CHEBI_63638 | |
| T4 | 79-92 | ChemicalEntity | denotes | Carbamazepine | http://purl.obolibrary.org/obo/CHEBI_3387|D002220 | |
| T3 | 39-49 | ChemicalEntity | denotes | vigabatrin | http://purl.obolibrary.org/obo/CHEBI_63638 | |
| T1 | 21-34 | ChemicalEntity | denotes | carbamazepine | D002220|http://purl.obolibrary.org/obo/CHEBI_3387 | |
| T98871 | 486-501 | DiseaseOrPhenotypicFeature | denotes | myoclonic jerks | D009207 | |
| T2 | 139-155 | DiseaseOrPhenotypicFeature | denotes | absence seizures | D012640 | |
| T61155 | 61-77 | DiseaseOrPhenotypicFeature | denotes | absence seizures | D012640 |
PubCasesHPO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| AB1 | 131-155 | HP:0011147 | denotes | typical absence seizures |
| TI1 | 53-77 | HP:0011147 | denotes | typical absence seizures |